Leiden, The Netherlands – DCPrime, a clinical stage company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne®, today announced that the Dutch Ministry of Economic Affairs, via its agency RVO (Rijksdienst voor Ondernemend Nederland), will support DCPrime B.V. for extending the applications of its lead product DCP-001 to other hematological malignancies.
DCP-001 already showed promise in patients with Acute Myeloid Leukemia (AML), and its properties make it suitable for other hematological cancers such as Multiple Myeoloma (MM) and Chronic Myeloid Leukemia (CML). RVO has now granted the company an “Innovation Credit” (soft loan) of €1.2 million to cover part of the costs of further clinical development of DCP-001 in such additional hematological indications. Together with the continued support of the Van Herk Group, this credit enables DCPrime to begin with testing applicability of its lead product DCP-001 in MM. RVO previously supported DCPrime’s successful DCP-001 vaccine program for AML, together with VC backing by Thuja Capital.
“We are very pleased with this continued support for our lead vaccine product DCP-001,” says Ada Kruisbeek, CEO and CSO of DCPrime. “There is a great need for new treatment options not only in patients with AML but also in MM and CML, but further studies are high risk. Nevertheless, regardless the results, these studies will provide further insights in best applicability of products based on our DCOne® platform technology as a sustainable source of DC that are endogenously loaded with various tumour antigens”. With this platform, DCPrime can generate vaccines against almost any cancer type.